Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
18. August 2022 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers
28. Juli 2022 09:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
20. April 2022 09:30 ET
|
Atossa Therapeutics, Inc.
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
27. Januar 2022 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
18. Januar 2022 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
30. September 2021 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...